Nu's U.S. Approval Boosts Optionality, But Near-Term Execution Risks Remain

What happened

Nu Holdings has received approval to expand into the United States, adding a new growth avenue to its core Latin American operations. The Motley Fool article highlights the digital bank's rapid growth and potential undervaluation, but the DeepValue report maintains a WAIT rating, emphasizing that near-term headwinds from a 2026 investment ramp and Mexico regulatory overhang temper the upside. The U.S. charter, while a positive optionality catalyst, introduces compliance costs and execution complexity that could pressure margins in the short term. Nu's strong Q4 2025 metrics—ARPAC of $15.0, efficiency ratio of 19.9%, and ROE of 33%—show robust underlying profitability, yet the stock at $14.5 discounts sustained outperformance without a margin of safety. The news does not alter the fundamental risk/reward calculus, as the key thesis breakers (efficiency ratio deterioration, Mexico interchange caps) remain unresolved.

Implication

The U.S. expansion approval is a positive catalyst that could enhance Nu's long-term growth narrative, but it does not alter the immediate risk calculus. The DeepValue report highlights that Nu's current price of ~$14.5 lacks a margin of safety given the 2026 investment ramp and potential Mexico interchange fee caps. Investors should wait for observable proof that the efficiency ratio stays contained (≤23%) and that credit quality (15-90 day NPL ≤4.1%) holds despite scaling. The U.S. charter process will add compliance costs and regulatory complexity, which could delay profitability in that market. Until these uncertainties resolve, the stock remains a hold; attractive entry levels are below $12, consistent with the bear case scenario.

Thesis delta

The U.S. approval shifts the narrative from pure LatAm compounding to a dual-market growth story, increasing optionality but also execution risk. However, it does not change the near-term thesis breakers: the 2026 efficiency ratio trajectory and Mexico regulatory outcome remain the dominant drivers. The thesis remains in a wait-and-see mode; a re-rating would require clear evidence that cost spending translates into ARPAC growth and stable credit, not just new market announcements.